{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:33:11Z","timestamp":1783053191688,"version":"3.54.6"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"DOI":"10.1007\/s13555-025-01474-3","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:27:58Z","timestamp":1751423278000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-2057","authenticated-orcid":false,"given":"Bruce","family":"Strober","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark I.","family":"Kaldas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"St. John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huzefa","family":"Photowala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam P.","family":"Sima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Eckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Beeghly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"issue":"10281","key":"1474_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/s0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301\u201315. https:\/\/doi.org\/10.1016\/s0140-6736(20)32549-6.","journal-title":"Lancet"},{"issue":"4","key":"1474_CR2","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.057.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1474_CR3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1177\/24755303231160683","volume":"8","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Gondo GC, Bell S, et al. Psoriasis involving special areas is associated with worse quality of life, depression, and limitations in the ability to participate in social roles and activities. J Psoriasis Psoriatic Arthritis. 2023;8(3):100\u20136. https:\/\/doi.org\/10.1177\/24755303231160683.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"1","key":"1474_CR4","doi-asserted-by":"publisher","first-page":"2287401","DOI":"10.1080\/09546634.2023.2287401","volume":"35","author":"B Strober","year":"2024","unstructured":"Strober B, Duffin KC, Lebwohl M, et al. Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry. J Dermatol Treat. 2024;35(1):2287401. https:\/\/doi.org\/10.1080\/09546634.2023.2287401.","journal-title":"J Dermatol Treat"},{"issue":"12","key":"1474_CR5","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1038\/jid.2015.296","volume":"135","author":"J Takeshita","year":"2015","unstructured":"Takeshita J, Gelfand JM, Li P, et al. Psoriasis in the US Medicare population: prevalence, treatment, and factors associated with biologic use. J Investig Dermatol. 2015;135(12):2955\u201363. https:\/\/doi.org\/10.1038\/jid.2015.296.","journal-title":"J Investig Dermatol"},{"issue":"2","key":"1474_CR6","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","volume":"84","author":"CA Elmets","year":"2021","unstructured":"Elmets CA, Korman NJ, Prater EF, et al. Joint AAD\u2013NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432\u201370. https:\/\/doi.org\/10.1016\/j.jaad.2020.07.087.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1474_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/jdv.16966","volume":"35","author":"NM Golbari","year":"2021","unstructured":"Golbari NM, van der Walt JM, Blauvelt A, Ryan C, van de Kerkhof P, Kimball AB. Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. J Eur Acad Dermatol Venereol. 2021;35(2):417\u201321. https:\/\/doi.org\/10.1111\/jdv.16966.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1474_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","volume":"82","author":"B Strober","year":"2020","unstructured":"Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117\u201322. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.026.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1474_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13555-023-01065-0","volume":"14","author":"ME Horner","year":"2024","unstructured":"Horner ME, Orroth KK, Ma J, Duan Y, Cordey M. Redefining disease severity with special area involvement and reflecting on treatment patterns in a real-world psoriasis population. Dermatol Ther (Heidelb). 2024;14(1):187\u201399. https:\/\/doi.org\/10.1007\/s13555-023-01065-0.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1474_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/24755303241302070","volume":"10","author":"B Strober","year":"2025","unstructured":"Strober B, Zhong Y, Sima A, et al. Criteria for identifying candidates for systemic psoriasis treatment in the real world: application of the International Psoriasis Council Guidelines in patients in North America. J Psoriasis Psoriatic Arthritis. 2025;10(1):22\u20137. https:\/\/doi.org\/10.1177\/24755303241302070.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"1474_CR11","unstructured":"AbbVie. Skyrizi-pi-english. 2022. https:\/\/www.rxabbvie.com\/pdf\/skyrizi_pi.pdf. Accessed 15 June 2023."},{"issue":"2","key":"1474_CR12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","volume":"76","author":"AW Armstrong","year":"2017","unstructured":"Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2016.10.017.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1474_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136. https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"1474_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365. https:\/\/doi.org\/10.2165\/00019053-199304050-00006.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1474_CR15","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jaad.2023.07.1024","volume":"89","author":"KA Papp","year":"2023","unstructured":"Papp KA, Blauvelt A, Puig L, et al. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial up to 5\u00a0years of follow-up. J Am Acad Dermatol. 2023;89(6):1149\u201358. https:\/\/doi.org\/10.1016\/j.jaad.2023.07.1024.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1474_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jaad.2023.08.097","volume":"90","author":"B Strober","year":"2024","unstructured":"Strober B, Ferris L, Duffin KC, et al. Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry. J Am Acad Dermatol. 2024;90(1):82\u201390. https:\/\/doi.org\/10.1016\/j.jaad.2023.08.097.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1474_CR17","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s13555-024-01164-6","volume":"14","author":"A Pinter","year":"2024","unstructured":"Pinter A, Soliman AM, Pivneva I, et al. Real-world long-term effectiveness of risankizumab among patients with moderate-to-severe psoriasis: analysis from an International Medical Chart Review (RAPID) study. Dermatol Ther (Heidelb). 2024;14(5):1259\u201371. https:\/\/doi.org\/10.1007\/s13555-024-01164-6.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1474_CR18","doi-asserted-by":"publisher","unstructured":"Carrascosa JM, Puig L, Romero IB, et al. [Translated article] Practical update of the recommendations published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the treatment of psoriasis with biologic therapy. Part 1. Concepts and general management of psoriasis with biologic therapy. Actas Dermo-Sifiliogr\u00e1ficas. 2022;113(3):T261\u2013T277. https:\/\/doi.org\/10.1016\/j.ad.2021.10.011.","DOI":"10.1016\/j.ad.2021.10.011"},{"issue":"11","key":"1474_CR19","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris\u2014part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461\u201398. https:\/\/doi.org\/10.1111\/jdv.16915.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1474_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MKA Basra","year":"2015","unstructured":"Basra MKA, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27\u201333. https:\/\/doi.org\/10.1159\/000365390.","journal-title":"Dermatology"},{"issue":"2","key":"1474_CR21","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.abd.2023.08.006","volume":"99","author":"R Romiti","year":"2024","unstructured":"Romiti R, Magalh\u00e3es RF, Duarte GV. Cumulative life course impairment in patients with dermatological diseases, with a focus on psoriasis. An Bras Dermatol. 2024;99(2):269\u201376. https:\/\/doi.org\/10.1016\/j.abd.2023.08.006.","journal-title":"An Bras Dermatol"},{"issue":"3","key":"1474_CR22","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40801-024-00439-w","volume":"11","author":"M Lebwohl","year":"2024","unstructured":"Lebwohl M, Strober B, Schrader A, et al. Six-month real-world study to assess the effectiveness of ixekizumab after switching from IL-23 inhibitors and other biologic therapies: the CorEvitas psoriasis registry. Drugs Real World Outcomes. 2024;11(3):451\u201364. https:\/\/doi.org\/10.1007\/s40801-024-00439-w.","journal-title":"Drugs Real World Outcomes"},{"issue":"9","key":"1474_CR23","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1007\/s13555-024-01238-5","volume":"14","author":"KB Gordon","year":"2024","unstructured":"Gordon KB, Blauvelt A, Bachelez H, et al. Long-term safety of risankizumab in patients with psoriatic disease: a comprehensive analysis from clinical trials. Dermatol Ther (Heidelb). 2024;14(9):2523\u201338. https:\/\/doi.org\/10.1007\/s13555-024-01238-5.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01474-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01474-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01474-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:27:59Z","timestamp":1751423279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01474-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":23,"alternative-id":["1474"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01474-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bruce Strober: Consultant (honoraria): AbbVie, Alumis, Almirall, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Capital One, CorEvitas, Dermavant, Janssen, LEO, Eli Lilly, Maruho, Oruka, Meiji Seika Pharma, Protagonist, Takeda, Novartis, Pfizer, UCB, RAPT, Regeneron, Sanofi-Genzyme, UNION Therapeutics; Stock Options: Connect Biopharma, Mindera Health; Speaker: AbbVie, Arcutis, Dermavant, Eli Lilly, Incyte, Janssen, Regeneron, Sanofi-Genzyme; Scientific Co-Director (consulting fee): CorEvitas Psoriasis Registry; Investigator: CorEvitas Psoriasis Registry; Editor-in-Chief (honorarium): Journal of Psoriasis and Psoriatic Arthritis. Manish Patel, Mark I. Kaldas, Greg St. John, and Huzefa Photowala are employees of AbbVie, Inc, and may hold AbbVie stock or stock options. Adam P. Sima, Thomas Eckmann, and Alicia Beeghly are employees of CorEvitas, LLC (formerly Corrona, LLC), and stockholders of Thermo Fisher Scientific, Inc. CorEvitas is supported through contracted subscriptions with multiple pharmaceutical companies. The manuscript was a collaborative effort between CorEvitas and AbbVie, with financial support provided by AbbVie. April Armstrong has served as a research investigator and\/or scientific adviser to AbbVie, ASLAN, Boehringer Ingelheim, Bristol Myers Squibb, EPI, Incyte, LEO, UCB, Janssen, Lilly, Novartis, Ortho Dermatologics, Sun, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and ModMed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practice (GPP). All participating investigators were required to obtain full board approval for conducting noninterventional research involving human subjects with a limited dataset. Sponsor approval and continuing review were obtained through a central institutional review board (IRB, Advarra, Protocol number is Pro00051221). For academic investigative sites that did not receive a waiver to use the central IRB, approval was obtained from the respective governing IRBs (see Table\u00a0 in the Electronic Supplementary Material for details), and documentation of approval was submitted to the sponsor prior to initiating any study procedures. All registry subjects were required to provide written informed consent prior to participating.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}